FI963272A0 - Uusi indolijohdannaisia, jotka ovat käyttökelpoisia hoitamaan estrogeeniin liittyviä kasvaimia ja sairauksia - Google Patents
Uusi indolijohdannaisia, jotka ovat käyttökelpoisia hoitamaan estrogeeniin liittyviä kasvaimia ja sairauksiaInfo
- Publication number
- FI963272A0 FI963272A0 FI963272A FI963272A FI963272A0 FI 963272 A0 FI963272 A0 FI 963272A0 FI 963272 A FI963272 A FI 963272A FI 963272 A FI963272 A FI 963272A FI 963272 A0 FI963272 A0 FI 963272A0
- Authority
- FI
- Finland
- Prior art keywords
- indole derivatives
- estrogen
- treatment
- derivatives useful
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
- C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20005794A | 1994-02-22 | 1994-02-22 | |
| US36204694A | 1994-12-22 | 1994-12-22 | |
| PCT/US1995/001372 WO1995022524A1 (en) | 1994-02-22 | 1995-01-31 | Novel indole derivatives useful to treat estrogen-related neoplasms and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI963272A FI963272A (fi) | 1996-08-21 |
| FI963272A0 true FI963272A0 (fi) | 1996-08-21 |
Family
ID=26895427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI963272A FI963272A0 (fi) | 1994-02-22 | 1996-08-21 | Uusi indolijohdannaisia, jotka ovat käyttökelpoisia hoitamaan estrogeeniin liittyviä kasvaimia ja sairauksia |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5877202A (fi) |
| EP (1) | EP0746544B1 (fi) |
| JP (1) | JP3536258B2 (fi) |
| KR (1) | KR100362864B1 (fi) |
| CN (1) | CN1141627A (fi) |
| AT (1) | ATE170839T1 (fi) |
| AU (1) | AU680740B2 (fi) |
| CA (1) | CA2183731C (fi) |
| DE (1) | DE69504637T2 (fi) |
| DK (1) | DK0746544T3 (fi) |
| ES (1) | ES2122555T3 (fi) |
| FI (1) | FI963272A0 (fi) |
| HU (1) | HUT76133A (fi) |
| IL (1) | IL112700A0 (fi) |
| NO (1) | NO963483L (fi) |
| NZ (1) | NZ281431A (fi) |
| WO (1) | WO1995022524A1 (fi) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5880137A (en) * | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| TW397821B (en) * | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
| US6200760B1 (en) * | 1997-02-24 | 2001-03-13 | Cornell Research Foundation, Inc. | Method of screening agents as candidates for drugs or sources of drugs |
| US6150395A (en) * | 1997-05-30 | 2000-11-21 | The Regents Of The University Of California | Indole-3-carbinol (I3C) derivatives and methods |
| US6069153A (en) * | 1998-05-12 | 2000-05-30 | American Home Products Corporation | Indenoindoles and benzocarbazoles as estrogenic agents |
| US6479535B1 (en) | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| JP2002515484A (ja) * | 1998-05-15 | 2002-05-28 | アメリカン・ホーム・プロダクツ・コーポレイション | ２−フェニルインドール化合物およびエストロゲン製剤からなる組成物 |
| US6207700B1 (en) * | 1999-01-07 | 2001-03-27 | Vanderbilt University | Amide derivatives for antiangiogenic and/or antitumorigenic use |
| US6159959A (en) * | 1999-05-06 | 2000-12-12 | American Home Products Corporation | Combined estrogen and antiestrogen therapy |
| CN1196708C (zh) * | 1999-09-13 | 2005-04-13 | 惠氏公司 | 2－(4－羟基－苯基)－1－[4－(2－氨－1－基－乙氧基)－苄基]－1h－吲哚－5－酚的吡喃葡糖苷轭合物 |
| DE19962300A1 (de) * | 1999-12-23 | 2001-06-28 | Asta Medica Ag | Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung |
| AU2001234958A1 (en) * | 2000-02-11 | 2001-08-20 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| US6326501B1 (en) * | 2000-04-19 | 2001-12-04 | Hoffmann-La Roche Inc. | Methylation of indole compounds using dimethyl carbonate |
| EP1324985A4 (en) * | 2000-10-02 | 2004-10-06 | Merck & Co Inc | PRENYL PROTEIN TRANSFERASE INHIBITORS |
| US20030130199A1 (en) * | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
| FR2842526B1 (fr) | 2002-07-16 | 2007-07-13 | Aventis Pharma Sa | Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments |
| AU2004226479A1 (en) * | 2003-03-27 | 2004-10-14 | Evotec Oai | Ophthalmic compositions for treating ocular hypertension |
| CN101031289A (zh) | 2004-04-26 | 2007-09-05 | 范德比尔特大学 | 作为具有降低胃肠毒性的治疗剂的吲哚乙酸和茚乙酸衍生物 |
| WO2007013872A2 (en) * | 2004-07-22 | 2007-02-01 | The Board Of Trustees Of The University Of Illinois | Sensors employing single-walled carbon nanotubes |
| RU2448703C2 (ru) * | 2005-11-23 | 2012-04-27 | Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем | Онкогенное ras-специфичное цитотоксическое соединение и способы его применения |
| EP2488025A4 (en) | 2009-10-15 | 2013-04-03 | Childrens Medical Center | SEPIAPTERIC INTREDUCTASE INHIBITION FOR PAIN TREATMENT |
| CA2845697C (en) | 2010-08-30 | 2020-05-05 | Arzeda Corp. | Fermentation route for the production of levulinic acid, levulinate esters, valerolactone, and derivatives thereof |
| EP3078374B1 (en) | 2011-10-17 | 2019-06-19 | Vanderbilt University | Indomethacin analogs for the treatment of castrate-resistant prostate cancer |
| WO2013102242A1 (en) | 2012-01-06 | 2013-07-11 | Spinifex Pharmaceuticals Pty Ltd | Heterocyclic compounds and methods for their use |
| US9182350B2 (en) * | 2012-03-05 | 2015-11-10 | Dalian University Of Technology | Naphthalene-based two-photon fluorescent probes, preparation method and use thereof |
| TWI747873B (zh) | 2016-02-01 | 2021-12-01 | 美商百歐克斯製藥公司 | 苯并吡唑化合物及其類似物 |
| US10815247B2 (en) * | 2016-12-28 | 2020-10-27 | Promega Corporation | Functionalized NANOLUC inhibitors |
| CA3217559A1 (en) * | 2021-05-05 | 2022-11-10 | Kamaluddin Abdur-Rashid | Catalytic tryptamine processes and precursors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH483421A (de) * | 1964-12-31 | 1969-12-31 | Merck & Co Inc | Verfahren zur Herstellung von 2-Phenyl-indolyl-Säuren |
| DK0431520T3 (da) * | 1989-12-04 | 1995-04-10 | Searle & Co | Heterocycliske acylaminodiol-beta-aminosyrederivater |
| EP0518961A1 (fr) * | 1990-03-07 | 1992-12-23 | Aventis Pharma S.A. | Derives de glycinamide, leur preparation et les medicaments les contenant |
| US5312928A (en) * | 1991-02-11 | 1994-05-17 | Cambridge Neuroscience | Calcium channel antagonists and methodology for their identification |
| EP0639567A1 (en) * | 1992-05-08 | 1995-02-22 | Otsuka Pharmaceutical Factory, Inc. | Indole derivative |
| JPH0835029A (ja) * | 1994-07-19 | 1996-02-06 | Toyota Motor Corp | 高強度高延性鋳造アルミニウム合金およびその製造方法 |
-
1995
- 1995-01-31 KR KR1019960704579A patent/KR100362864B1/ko not_active IP Right Cessation
- 1995-01-31 CN CN95191750A patent/CN1141627A/zh active Pending
- 1995-01-31 DE DE69504637T patent/DE69504637T2/de not_active Expired - Lifetime
- 1995-01-31 JP JP52182295A patent/JP3536258B2/ja not_active Expired - Lifetime
- 1995-01-31 AU AU18373/95A patent/AU680740B2/en not_active Ceased
- 1995-01-31 DK DK95910164T patent/DK0746544T3/da active
- 1995-01-31 WO PCT/US1995/001372 patent/WO1995022524A1/en active IP Right Grant
- 1995-01-31 NZ NZ281431A patent/NZ281431A/en unknown
- 1995-01-31 ES ES95910164T patent/ES2122555T3/es not_active Expired - Lifetime
- 1995-01-31 HU HU9602299A patent/HUT76133A/hu unknown
- 1995-01-31 CA CA002183731A patent/CA2183731C/en not_active Expired - Lifetime
- 1995-01-31 AT AT95910164T patent/ATE170839T1/de not_active IP Right Cessation
- 1995-01-31 EP EP95910164A patent/EP0746544B1/en not_active Expired - Lifetime
- 1995-02-20 IL IL11270095A patent/IL112700A0/xx unknown
-
1996
- 1996-01-31 US US08/594,505 patent/US5877202A/en not_active Expired - Lifetime
- 1996-08-21 NO NO963483A patent/NO963483L/no unknown
- 1996-08-21 FI FI963272A patent/FI963272A0/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2183731A1 (en) | 1995-08-24 |
| DE69504637D1 (de) | 1998-10-15 |
| DE69504637T2 (de) | 1999-05-06 |
| EP0746544A1 (en) | 1996-12-11 |
| HUT76133A (en) | 1997-06-30 |
| FI963272A (fi) | 1996-08-21 |
| NO963483L (no) | 1996-10-22 |
| ATE170839T1 (de) | 1998-09-15 |
| ES2122555T3 (es) | 1998-12-16 |
| CN1141627A (zh) | 1997-01-29 |
| NZ281431A (en) | 1997-09-22 |
| CA2183731C (en) | 2000-03-21 |
| NO963483D0 (no) | 1996-08-21 |
| WO1995022524A1 (en) | 1995-08-24 |
| DK0746544T3 (da) | 1999-06-07 |
| AU1837395A (en) | 1995-09-04 |
| JP3536258B2 (ja) | 2004-06-07 |
| HU9602299D0 (en) | 1996-10-28 |
| EP0746544B1 (en) | 1998-09-09 |
| JPH09509169A (ja) | 1997-09-16 |
| IL112700A0 (en) | 1995-05-26 |
| US5877202A (en) | 1999-03-02 |
| KR100362864B1 (ko) | 2003-04-16 |
| AU680740B2 (en) | 1997-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI963272A0 (fi) | Uusi indolijohdannaisia, jotka ovat käyttökelpoisia hoitamaan estrogeeniin liittyviä kasvaimia ja sairauksia | |
| ATE228003T1 (de) | Verwendung von cntf (ciliary neurotrophic factor) rezeptoraktivatoren fur behandlung von fettleibigkeit | |
| EA199700044A1 (ru) | Эстрогенные агенты | |
| DE69521620D1 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
| AR005987A1 (es) | Terapia combinada para la osteoporosis | |
| ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
| DK155143C (da) | Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet | |
| DE69839815D1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
| BR0206985A (pt) | Anticorpos modificados e métodos de uso | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| ATE282413T1 (de) | Verwendung von tempol zur behandlung von essentiellem hochdruck | |
| DE69910830D1 (de) | Verbindungen und verfahren zur modulation von estrogen rezeptoren | |
| DE69725879D1 (de) | VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN | |
| ATE292468T1 (de) | Verwendung von biogenen estrogensulfamaten zur hormonsubstitutionstherapie | |
| ATE210447T1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
| BR0008076A (pt) | 16-hidroxiestratrienos como estrogênios de efeito seletivo | |
| BG105125A (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone | |
| ATE255094T1 (de) | Piperazinderivate zur behandlung der niedrigen harnwege | |
| DE60005952T8 (de) | Lösliche hla-g enthaltende zusammensetzungen zur behandlung entzündlicher hautkrankheiten | |
| NO994903L (no) | Behandling eller profylakse av prostatakreft og benign prostatahyperplasi med selektive östrogenreseptormodulatorer | |
| ATE293994T1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
| NO980375L (no) | Humant MP52 Arg protein | |
| RU2000126276A (ru) | Лекарственный препарат для профилактики и/или лечения рака молочной железы, содержащий стероидный ингибитор ароматазы | |
| Shah et al. | Bridging technique and science: A review of the molecular signals from long bone development that guiding bone regeneration | |
| ATE168697T1 (de) | Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen |